Sintilimab, Anlotinib Hydrochloride and Platinum-Containing Dual-Agent Chemotherapy in NSCLC

Clinical trial NCT04846452 · UNKNOWN

Trial details

NCT number: NCT04846452
Sponsor: The First Affiliated Hospital with Nanjing Medical University
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Metastatic NSCLC Recurrent NSCLC Advanced Non-Small Cell Squamous Lung Cancer

Start date: 2021-06-01
Primary completion: 2023-05-01
Enrollment: 40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.